Business Wire

Cyara Resolves Common Chatbot Failures with New Testing Capabilities

19.7.2022 18:00:00 EEST | Business Wire | Press release

Share

Cyara, provider of the award-winning Automated Customer Experience (CX) Assurance Platform, today unveiled innovative new chatbot testing features with the latest release of Cyara Botium, the industry’s leading one-stop solution for comprehensive, automated chatbot testing and assurance. The release comes just weeks after Cyara announced its acquisition of Botium to solidify its position as the global leader in CX testing and assurance.

Chatbots continue to experience tremendous growth driven by the meaningful benefits they deliver to businesses and customers alike, but they’re also commonly plagued with problems that include misinterpreted customer intent, delayed or disrupted hand-offs to live agents and security vulnerabilities. Negative chatbot experiences can have a devastating impact on a brand and result in customer churn.

The disconnect between what chatbots generally promise and what they deliver has created the need for solutions that can efficiently test and monitor the performance of chatbots and conversational AI without overburdening teams. With Cyara Botium’s holistic testing approach, brands can improve and continuously test the customer chatbot experience across all channels and platforms in all phases of the chatbot development lifecycle. Cyara Botium also addresses the rise in chatbot data breaches by improving general chatbot security, ensuring compliance with Open Web Application Security Project® (OWASP) security standards. The result: consistent, quality, secure experiences and, for new bots, shortened time to market.

Cyara Botium offers the following new features and capabilities:

AI-Powered Data & Test Generation

Cyara Botium’s new AI-Powered Data & Test Generation is built on the world’s largest natural language model. This enables organizations to quickly create relevant examples of intents and utterances in order to thoroughly train and test their chatbots. This cutting-edge feature dramatically improves the efficiency of chatbot teams, requiring mere minutes to generate new intent phrasing to the chatbot—an otherwise laborious, manual process that can take weeks to collect data from various sources. By using the largest pre-trained language model through Cyara Botium, customers can save AI-generated topics as new intents – thereby dramatically improving the chatbot’s ability to understand what the user is trying to achieve.

Extended Performance Testing

Cyara Botium has greatly enhanced the scalability of its performance testing by dramatically increasing the capacity of parallel test executions so that chatbot development teams can stress test by simulating very high volumes of interactions.

Interactive Voice Response (IVR) Channel and Voice Testing

The new release of Cyara Botium introduces two new test types. Users can now test bots in the IVR channel, ensuring they perform effectively as part of an IVR experience by generating calls that mimic real-time customer interactions. Users can also now conduct voice tests to ensure voicebots perform well in all environments, including mobile devices and browsers. Both of these new features ensure problems are unearthed well before they occur in production.

“It’s without question that chatbots are delivering benefits to businesses, but it’s imperative that organizations also realize that negative chatbot experiences can lead to chatbots hurting the business more than they help,” said Christoph Börner, Senior Director of Digital at Cyara. “Cyara Botium has already been a prominent market leader in testing conversational AI and is well ahead of the market needs. The innovative features introduced in this release reinforce our leadership, setting us even further ahead of any competition.”

Additional new features include multi-language General Data Protection Regulation (GDPR) testing for compliance with European Union (EU) security protocols, customizable reporting templates that appeal to any stakeholder and Single Sign-On (SSO) user authentication.

To learn more about Cyara Botium, please click here.

About Cyara’s Automated CX Assurance Platform

The award-winning Cyara Automated CX Assurance Platform enables companies to deliver better CX with less effort, cost, and risk. Cyara supports the entire CX software development lifecycle, from design to functional and regression testing, load testing, chatbot testing and production monitoring, ensuring enterprises can build flawless customer journeys across voice and digital channels.

About Cyara

Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. Every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Diana Gallagher
10Fold Communications for Cyara
Cyara@10fold.com
(408) 656-9699

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release

Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release

For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye